Safety and interim results from a phase II, single-arm study of atezolizumab and bevacizumab in Merkel cell carcinoma (MCC).

被引：1
|
作者：
Ferrarotto, Renata
Mata, Javier
Mott, Frank
Bhosale, Priya
Rubin, M. Laura
Altan, Mehmet
Dervin, Shannon
Yun, Cindy
Yao, James C.
Halperin, Daniel M.
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Div Canc Med, Houston, TX 77030 USA
[3] Genentech Inc, San Francisco, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e21006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21006
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study
    Plimack, E. R.
    Jonasch, E.
    Bekele, B. N.
    Qiao, W.
    Ng, C. S.
    Tannir, N. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [2] Atezolizumab plus bevacizumab in advanced Merkel cell carcinoma: A prospective study
    de Sousa, L. Guimaraes
    Liu, S.
    Bhosale, P.
    Altan, M.
    Darbonne, W.
    Schulze, K.
    Dervin, S.
    Yun, C.
    Mahvash, A.
    Verma, A.
    Futreal, A.
    Gite, S.
    Cuentas, E. Parra
    Cho, W. C.
    Wistuba, I.
    Yao, J. C.
    Woodman, S. E.
    Halperin, D. M.
    Ferrarotto, R.
    ORAL ONCOLOGY, 2024, 151
  • [3] Transcatheter arterial chemoembolization plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: a single-arm, phase 2 trial
    Wang, Kang
    Yu, Hong-Ming
    Xiang, Yan-Jun
    Cheng, Yu-Qiang
    Ni, Qian-Zhi
    Guo, Wei-Xing
    Shi, Jie
    Feng, Shuang
    Zhai, Jian
    Cheng, Shu-Qun
    FUTURE ONCOLOGY, 2022, 18 (30) : 3367 - 3375
  • [4] Atezolizumab for Cisplatin-Inappropriate Patients with advanced or metastatic Urothelial Carcinoma Results of single-arm Phase-II-Study (IMvigor 210)
    Wezel, Felix
    Bolenz, Christian
    ONKOLOGE, 2017, 23 (10): : 858 - 860
  • [5] FOLFOX-HAIC combined with sintilimab and bevacizumab for advanced hepatocellular carcinoma: A single-arm, phase II study
    Wang, Z.
    Zheng, C.
    Liang, B.
    ANNALS OF ONCOLOGY, 2024, 35 : S1483 - S1483
  • [6] Atezolizumab plus Bevacizumab in Patients with Unresectable or Metastatic Mucosal Melanoma: A Multicenter, Open-Label, Single-Arm Phase II Study
    Mao, Lili
    Fang, Meiyu
    Chen, Yu
    Wei, Xiaoting
    Cao, Jun
    Lin, Jing
    Zhang, Peng
    Chen, Ling
    Cao, Xiao
    Chen, Yujun
    Guo, Jun
    Si, Lu
    CLINICAL CANCER RESEARCH, 2022, 28 (21) : 4642 - 4648
  • [7] Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer
    Gonzalez-Martin, Antonio
    Gladieff, Laurence
    Tholander, Bengt
    Stroyakovsky, Daniel
    Gore, Martin
    Scambia, Giovanni
    Kovalenko, Nadezhda
    Oaknin, Ana
    Ronco, Julian Perez
    Freudensprung, Ulrich
    Pignata, Sandro
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (18) : 3831 - 3838
  • [8] Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
    Xiaoqiang Gao
    Rui Zhao
    Huaxing Ma
    Shi Zuo
    BMC Cancer, 23
  • [9] Efficacy and safety of atezolizumab plus bevacizumab treatment for advanced hepatocellular carcinoma in the real world: a single-arm meta-analysis
    Gao, Xiaoqiang
    Zhao, Rui
    Ma, Huaxing
    Zuo, Shi
    BMC CANCER, 2023, 23 (01)
  • [10] Neoadjuvant Nivolumab Therapy for Esophageal Squamous Cell Carcinoma: A Single-Arm, Phase II Study
    Park, Sehhoon
    Lee, Yurimi
    Lee, Jiyun
    Min, Yang Won
    Kim, Hong Kwan
    Chol, Joon Young
    Jung, Hyun Ae
    Choi, Yong Soo
    Choi, Yoon-La
    Shim, Young Mog
    Sun, Jong-Mu
    CANCER RESEARCH AND TREATMENT, 2024, 56 (02): : 567 - 579
12345